ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Forxiga successful in DAPA-HF heart failure trial
March 31, 2020New data from a sub-analysis of AstraZeneca’s Phase III DAPA-HF trial has shown that Forxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo. -
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
August 21, 2019AstraZeneca announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and ...
Pharma Sources Insight January 2025
